Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
Amyotrophic Lateral Sclerosis
Brown Adipose Tissue in ALS
Weight loss is a common phenomenon in ALS. During the course of the disease, difficulty in swallowing and mastication can be responsible for a decrease in caloric intake and thus for weight loss.
- Trial name
- BATALS (NCT03150290)
- Testing
- Indirect Calorimetry., 18-FDG-PET
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Validation of a New Device to Measure Neuromuscular Disease Progression
There is a great need for the development of sensitive outcomes that allow experimental drugs to be tested in human subjects more efficiently.
- Trial name
- ATLIS (NCT00606918)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
- Trial name
- NCT06609213
- Testing
- Medical Food
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andrea Charvet
Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral…
- Trial name
- TUDCA-ALS (NCT03800524)
- Testing
- Tauroursodeoxycholic Acid
- Where
- 25 sites in Belgium, France and 5 more
- Volunteers
- 337 people
- Sponsor
- Humanitas Mirasole SpA
COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis)
Psilocybin Therapy for Psychological Distress in Palliative Patients
The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD)
- Trial name
- PsyPal (NCT06782724)
- Testing
- Psilocybin therapy
- Where
- 4 sites in Czechia, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- University Medical Center Groningen
Frontotemporal Dementia (FTD), GRN Related Frontotemporal Dementia
Predict to Prevent PGRN Disease
Progranulin (GRN or PGRN) mutations are among the most common genetic causes of frontotemporal lobar degeneration (FTLD). With the advent of gene-specific therapeutic interventions, an accurate knowledge of the presymptomatic…
- Trial name
- PREVENT-PGRN (NCT06711510)
- Testing
- Clinical, behavioral and cognitive evaluation, blood sampling, brain MRI
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Motor Neuron Diseases
Collection of Blood Samples for DNA in Motor Neuron Disease
This study will collect blood samples from patients with primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) to be used for research on genetic causes of motor neuron diseases and other neurological disorders.
- Trial name
- NCT00362362
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02988297
- Testing
- RNS60
- Sponsor
- Revalesio Corporation
Amyotrophic Lateral Sclerosis
Ultra-high-caloric, Fatty Diet in ALS
This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- LIPCAL-ALS II (NCT06280079)
- Testing
- Ultra-high-caloric fatty diet
- Where
- 23 sites in Germany
- Volunteers
- 399 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients
Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders.
- Trial name
- NCT04654689
- Testing
- Liposomed polyphenols resveratrol and curcumin, Isocaloric Diet, G04CB02
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)
MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).
- Trial name
- MetFlex (NCT04788745)
- Testing
- Trimetazidine Dihydrochloride
- Where
- 3 sites in Australia, Netherlands and 1 more
- Volunteers
- 21 people
- Sponsor
- The University of Queensland
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Amyotrophic Lateral Sclerosis (ALS)
A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)
This is a first-in-human study of NI112, an investigational medicine given as an injection under the skin, in adults with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07906665
- Testing
- NI112
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sachi Bioworks Inc.
Depression, Amyotrophic Lateral Sclerosis
SSRIs vs. TCAs for Depression in ALS Patients
Depression is seen in 9-11% of ALS patients and adequate and proper treatment is needed. In this study, ALS patients will be screened for depression using self-reported multiple choice questionnaire.
- Trial name
- NCT02851914
- Testing
- Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI")
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- St. Louis University
Amyotrophic Lateral Sclerosis
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by…
- Trial name
- JETALS (NCT03548311)
- Testing
- methylcobalamin, saline solution
- Where
- 16 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Disease, FTD
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and…
- Conditions
- Alzheimer Disease, FTD, Young-onset Dementia, MCI
- Trial name
- NeurOmics (NCT07235111)
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Ospedale Policlinico San Martino
Amyotrophic Lateral Sclerosis
Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients
Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, is a fatal progressive neurodegenerative disease affecting motor cortex, brainstem and spinal cord leading to motor neuron death.
- Trial name
- NCT03377309
- Testing
- Fycompa
- Where
- Lebanon
- Volunteers
- 6 people
- Sponsor
- American University of Beirut Medical Center
Amyotrophic Lateral Sclerosis (ALS)
Individualized Functional Imaging-Guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Postural Gait Disorders in Patients with Amyotrophic Lateral Sclerosis (ALS): a Randomized, Crossover, Controlled, Double-Blind Clinical Study
This study is a randomized, crossover, controlled, double-blind clinical trial. Patients (n=45) were randomly divided into Group A and Group B.
- Trial name
- iFIRST-ALS (NCT06819358)
- Testing
- Transcranial Magnetic Stimulation
- Volunteers
- 45 people
- Sponsor
- Peking University Third Hospital
MND (Motor Neurone DIsease)
MND Together: Phase 1
This project consists of two workstreams, both of which will be mixed-methods and aim to develop a national UK picture of current care coordination for people with MND, including observations of barriers and facilitators.
- Trial name
- NCT07393932
- Testing
- Not applicable- observational study
- Where
- United Kingdom
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- University of Sheffield